ACAT2 and ductal breast carcinoma in situ: The upregulation of ACAT2 transcripts in inherently statin-resistant MCF10.DCIS cells suggests that avasimibe (an ACAT2 inhibitor) could be a potential target for combination with fluvastatin to sensitize these cells.